Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
OKX Explorer Expands Ecosystem Coverage with Sonic Integration
-
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
-
Velcan Holdings: Share buyback program - weekly statement
-
Denny’s Canada is serving up the perfect dish to help spread awareness and end food insecurity in Ontario
-
Form 8.3 - [KEYWORDS STUDIOS PLC - 13 09 2024] - (CGWL)
-
Form 8.3 - [ECKOH PLC - 13 09 2024] - (CGWL)
-
Octa broker forecast: what factors will affect the gold rate in India
-
MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers
-
Endeavour Announces Holding(s) in Company
-
Birmingham City and Delta Air Lines join forces for 2024-2025 season
-
Micro3 Launches GENE-a-Multiverse: Play, Share & Get Rewarded This Mid-Autumn Festival
-
Vietnam’s Thriving Textile Sector Shines at VTG 2024
-
VIO Med Spa Announces Majority Investment from Freeman Spogli
-
Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe
-
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
-
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
-
Nova Klúbburinn hf.: Framkvæmd endurkaupaáætlunar í viku 37
-
2Xideas Appoints Northern Trust for Integrated Trading Solutions
-
S64 Appoints Gaurav Katyal as Chief Operating Officer for Asia Pacific
-
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
-
Vantage Copy Trading premieres another dynamic video as it introduces new exciting features
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Keywords Studios plc
-
Genesis AI Launches Wildfire Defence Solutions V 1.2
-
USTOA INVITES TRAVELERS TO ENTER "PICTURE YOURSELF IN…" SWEEPSTAKES
-
Maison Law Accident & Injury Lawyers Donates a New, One-of-a-Kind Outdoor Mobility Training Facility to Kaweah Health Rehabilitation Hospital in Visalia
-
BNY to Launch Alts Bridge Platform Broadening Investor Access to Alternative Products
-
Stratasys Announces Board Authorization of $50 Million Share Repurchase Program
-
Barclays Doubles Private Cloud Estate With HPE GreenLake Cloud
-
Nokia selected by CoreWeave to provide networking backbone behind hyperscale AI cloud
-
Man Group PLC : Form 8.3 - Spirent Communications plc
-
Man Group PLC : Form 8.3 - International Paper Company
-
Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes
-
Man Group PLC : Form 8.3 - AngloGold Ashanti plc
-
Man Group PLC : Form 8.3 - Centamin plc
-
Danske Bank share buy-back programme: Transactions in week 37
-
ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer
-
ATS to Participate in Aviation Africa 2024
-
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive pro
-
Danske Bank A/S, transactions by persons discharging managerial responsibilities
-
SHARE BUYBACK TRANSACTIONS
-
Dimensional Fund Advisors Ltd. : Form 8.3 - VIRGIN MONEY UK PLC - Ordinary Shares
-
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SEGRO plc - Ordinary Shares
-
Prepayments, Realkredit Danmark A/S
-
Dimensional Fund Advisors Ltd. : Form 8.3 - RIGHTMOVE PLC - Ordinary Shares
-
Sydbank share buyback programme: transactions in week 37
-
PHINIA Publishes Industry-Leading Guide to Global Emission Regulations
-
Dimensional Fund Advisors Ltd. : Form 8.3 - REA GROUP LTD - Ordinary Shares
-
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PAPER CO - Ordinary Shares
